Pfizer’s Velsipity UK approval will raise competition in ulcerative colitis market, says GlobalData
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
The average time of dilation lasts three to eight hours
Application based on results from the TROPION-Breast01 Phase III trial
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
USFDA inspects Zydus Lifesciences’ Ahmedabad SEZ Onco manufacturing plant
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
The facility will manufacture tablets, capsules, and injections for the oncology segment
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Subscribe To Our Newsletter & Stay Updated